{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-050880","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.099832+00:00","generated_at":"2026-05-25T01:29:09.952868+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Viridian Therapeutics appoints Christopher Cain to board; Peter Harwin resigns effective March 10","bullets":["Christopher Cain (Director of Research, Fairmount Funds Management) named Class I director and chair of Nominating and Corporate Governance Committee.","Peter Harwin resigned from the board effective March 10, 2025, with no disagreement with the company.","Cain also joins the Audit Committee and Science & Technology Committee; standard director compensation applies.","Cain previously served at Samsara BioCapital, Apple Tree Partners, RA Capital Management, and BioCentury."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-050880","json":"https://secwatch.observer/filing/0001193125-25-050880.json","markdown":"https://secwatch.observer/filing/0001193125-25-050880.md","text":"https://secwatch.observer/filing/0001193125-25-050880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/0001193125-25-050880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/d937334d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:29:09.952868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43bfdcfdd9","claim":"Peter Harwin resigned as Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On March 5, 2025, Peter Harwin, a member of the Board, notified the Company of his decision to resign as a member of the Board effective as of March 10, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/0001193125-25-050880-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4ea31f13d5","claim":"Christopher Cain was appointed as Class I Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"appointed Christopher Cain, Ph.D., the Director of Research at Fairmount Funds Management LLC, to serve as a Class I director of the Company, chairperson of the Nominating and Corporate Governance Committee, and member of the Audit Committee and Science & Technology Committee, effective as of March 10, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/0001193125-25-050880-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}